Ken Griffin Bio Techne Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$70.96 - $82.35 $596,064 - $691,740	-8,400 Reduced 19.31%	35,100 $2.8 Million
Q2 2024 Aug 14, 2024	BUY	$62.12 - $84.15 $329,236 - $445,995	5,300 Added 13.87%	43,500 $3.12 Million
Q1 2024 May 15, 2024	BUY	$65.98 - $77.09 $1.23 Million - $1.43 Million	18,600 Added 94.9%	38,200 $2.69 Million
Q4 2023 Feb 14, 2024	BUY	$52.83 - $78.22 $644,526 - $954,284	12,200 Added 164.86%	19,600 $1.51 Million
Q3 2023 Nov 14, 2023	SELL	$67.52 - $89.42 $1.86 Million - $2.46 Million	-27,500 Reduced 78.8%	7,400 $503,000
Q2 2023 Aug 14, 2023	BUY	$73.76 - $85.98 $1.34 Million - $1.56 Million	18,200 Added 108.98%	34,900 $2.85 Million
Q1 2023 May 15, 2023	SELL	$71.62 - $86.62 $952,546 - $1.15 Million	-13,300 Reduced 44.33%	16,700 $1.24 Million
Q4 2022 Feb 14, 2023	BUY	$80.67 - $352.29 $1.57 Million - $6.87 Million	19,500 Added 185.71%	30,000 $2.49 Million
Q3 2022 Nov 14, 2022	BUY	$282.54 - $391.85 $1.36 Million - $1.88 Million	4,800 Added 84.21%	10,500 $2.98 Million

601

151M

195K

53.2K

Ticker TECH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,222,600
Market Cap $2.8B
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.